300391 *ST长药控股
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)23.696528.321-121.642-2.8616.127
总资产报酬率 ROA (%)-5.832-23.081-17.244-0.5971.104
投入资产回报率 ROIC (%)-47.888-86.756-42.419-1.2502.458

边际利润分析
销售毛利率 (%)3.658-6.42016.22421.46822.686
营业利润率 (%)-200.474-1,192.201-55.9234.9497.490
息税前利润/营业总收入 (%)-163.297-1,180.115-51.7757.5888.383
净利润/营业总收入 (%)-200.508-1,288.846-59.0652.7596.746

收益指标分析
经营活动净收益/利润总额(%)52.40217.057-2.344176.705153.935
价值变动净收益/利润总额(%)-1.5510.308-9.93176.834-0.666
营业外收支净额/利润总额(%)0.2646.7881.659-11.305-11.744

偿债能力分析
流动比率 (X)0.5330.5871.1321.1270.976
速动比率 (X)0.5070.5651.1041.0890.883
资产负债率 (%)128.221121.11370.47653.48461.815
带息债务/全部投入资本 (%)562.957203.39079.14953.13347.998
股东权益/带息债务 (%)-85.766-57.17822.92384.65488.547
股东权益/负债合计 (%)-21.475-17.9088.03541.83331.717
利息保障倍数 (X)-4.330-11.931-10.1702.4164.991

营运能力分析
应收账款周转天数 (天)2,513.0834,223.362461.156312.784195.764
存货周转天数 (天)130.225142.90319.97436.15844.056